Company Shakeups

Jazz Pharmaceuticals in Trouble… Still

I always felt a company marketing a date rape drug (GHB) and an antidote for antifreeze (ethylene glycol) poisoning was in for a world of hurt. 

The stock is down 62.5% ($6.75 from $18) from the IPO almost a year ago and today the company filed an S3 with the SEC allowing the sale of $100 million of its common or preferred stock, warrants or debt securities in addition to announcing layoff of 8% of its workforce and the delay of some developmental programs.

Buckle up.  It’s only gonna get bumpier.

PS: If you ever find yourself having just ingested antifreeze, don’t reach for the Antizol, just head to the pub and down some shots.  Cheaper and more fun!

Theoretically Related Posts

• July 25, 2008 -- AutoGenomics Files for IPO (0)
• May 13, 2008 -- Aldagen Files andIPO Despite Tough Market (0)
• April 28, 2008 -- Elixir Hoping to Cash In On Sirtuins Too After GSK / Sirtris Deal (0)
• April 24, 2008 -- Biotech/Pharma Competitive Intelligence (1)

© 2008 Pharmababble.